SUMO1 knockdown reversed PARP1 inhibitors-caused amelioration of cardiac hypertrophy in PE-treated NRCMs, as revealed by the increased protein level of ANF (Figure 7G), increased ANF and BNP mRNA levels (Figure 7H), and the increased cell surface area (Figure 7I). Here, SUMO1 is linked to cardiac hypertrophy.